title: Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors.
abstract: By examining inhibitor interactions with single and multiple site-specific mutants of mouse acetylcholinesterase, we have identified three distinct domains in the cholinesterase structure that are responsible for conferring selectivity for acetyl- and butyrylcholinesterase inhibitors. The first domain is the most obvious; it defines the constraints on the acyl pocket dimensions where the side chains of F295 and F297 primarily outline this region in acetylcholinesterase. Replacement of these phenylalanine side chains with the aliphatic residues found in butyrylcholinesterase allows for the catalysis of larger substrates and accommodates butyrylcholinesterase-selective alkyl phosphates such as isoOMPA. Also, elements of substrate activation characteristic of butyrylcholinesterase are evident in the F297I mutant. Substitution of tyrosines for F295 and F297 further alters the catalytic constants. The second domain is found near the lip of the active center gorge defined by two tyrosines, Y72 and Y124, and by W286; this region appears to be critical for the selectivity of bisquaternary inhibitors, such as BW284C51. The third domain defines the site of choline binding. Herein, in addition to conserved E202 and W86, a critical tyrosine, Y337, found only in the acetylcholinesterases is responsible for sterically occluding the binding site for substituted tricyclic inhibitors such as ethopropazine. Analysis of a series of substituted acridines and phenothiazines defines the groups on the ligand and amino acid side chains in this site governing binding selectivity. Each of the three domains is defined by a cluster of aromatic residues. The two domains stabilizing the quaternary ammonium moieties each contain a negative charge, which contributes to the stabilization energy of the respective complexes.
authors.affiliation: Department of Pharmacology, University of California at San Diego, La Jolla 92093-0636.
authors.forename: Z
authors.initials: Z
authors.lastname: Radić
authors.forename: N A
authors.initials: NA
authors.lastname: Pickering
authors.forename: D C
authors.initials: DC
authors.lastname: Vellom
authors.forename: S
authors.initials: S
authors.lastname: Camp
authors.forename: P
authors.initials: P
authors.lastname: Taylor
mesh_terms: D000110:Acetylcholinesterase / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D002091:Butyrylcholinesterase / Q000737:chemistry* / Q000378:metabolism; D002478:Cells, Cultured; D002800:Cholinesterase Inhibitors / Q000378:metabolism*; D002802:Cholinesterases / Q000737:chemistry* / Q000378:metabolism; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000378:metabolism; D013379:Substrate Specificity; D014101:Torpedo
chemical_list: D002800:Cholinesterase Inhibitors; D011993:Recombinant Fusion Proteins; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002802:Cholinesterases